Scarica l'app Stockscreener
37.96
0.16%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$38.02
Aprire:
$38.39
Volume 24 ore:
11.56M
Relative Volume:
0.51
Capitalizzazione di mercato:
$168.68B
Reddito:
$46.77B
Utile/perdita netta:
$15.45B
Rapporto P/E:
10.95
EPS:
3.468
Flusso di cassa netto:
$4.40B
1 W Prestazione:
-1.61%
1M Prestazione:
-23.42%
6M Prestazione:
-30.82%
1 anno Prestazione:
-49.98%
Intervallo 1D:
$37.70
$38.80
Intervallo di 1 settimana:
$37.70
$39.88
Portata 52W:
$35.85
$82.57
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVO vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
37.96 | 168.68B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Downgrade | TD Cowen | Buy → Hold |
| 2026-03-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Downgrade | Goldman | Buy → Neutral |
| 2026-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Downgrade | Kepler | Buy → Hold |
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Aggiornamento | Jefferies | Underperform → Hold |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm
Is Eli Lilly's Weight Loss Empire in Trouble? - The Motley Fool
NVO Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - ChartMill
Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs - Finviz
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - Finviz
Novo Nordisk 2026 Dividend Guide for UAE Investors - Bitget
Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From UnderweightHere's Why - Finviz
Novo Nordisk Faces Securities Probe And GLP-1 Compounding Crackdown - Sahm
Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B - Finviz
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Sahm
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
NVO Earnings History & Surprises | EPS & Revenue Results | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk’s New Sogroya Uses And Vivtex Deal Test Valuation Gap - Sahm
JPMorgan prices Digital Barrier Notes linked to Novo Nordisk (AMJB) with 24.25% digital return - Stock Titan
Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya - Finviz
Novo Nordisk A/S - TradingView
Novo Nordisk A/S (NVO) and Vivtex Corporation Announce a Partnership - Finviz
Novo Nordisk Sales Warning Tests GLP-1 Reliance And Future Growth Story - Sahm
NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com
Novo Nordisk's Shares Drop 16.43% on CagriSema Setback and Legal Scrutiny Trading Volume Slides to 184th - Bitget
Jim Cramer Recommends Eli Lilly over Novo Nordisk - Finviz
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment - Finviz
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
Ozempic Price War - Benzinga
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Sahm
Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal agains - The Economic Times
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Novo Nordisk: Another Disappointing Cagrisema Trial Adds Pressure to High-Dose Strategy - Morningstar
Novo Nordisk Is Losing Share, but We Still See Its Portfolio and Pipeline Supporting a Wide Moat - Morningstar
Stock Of The Day: Breakdown In Novo Nordisk? - Finviz
Pre-market Overview | Uncertainty looms over US tariff policy! All three major futures indices trend lower; popular Chinese ADRs active in pre-market trading, with PDD Holdings up over 3%; Novo-Nordisk A/S plunges 14% as its next-generation weight-loss dr - 富途牛牛
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):